Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > “Outperform” rating reiterated today by RBC analysts
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(72)
•••
Comment by TickerTwiton Jul 05, 2016 3:15pm
76 Views
Post# 25024322

RE:“Outperform” rating reiterated today by RBC analysts

RE:“Outperform” rating reiterated today by RBC analystsI have RBCCM's latest target at USD$40, first issued Jun/24, repeated yesterday. CAD$52 at today's CAD/USD rate.
.
TOMMY1 wrote:
Analyst: RBC Capital Markets
Rating: Outperform (reiterated)
Price target: CA$51 (potential upside of 79.58% from yesterday's close)

https://www.stocktargetprices.com/company/Concordia%20Healthcare%20Corp

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities